Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a renewed ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

The State Street SPDR S&P Biotech ETF, which trades under the ticker XBI, was down 2.1% on Monday morning, a sign of a shift ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on the surface. Year-to-date, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

In this article, we will look at the 14 Best Biotech Penny Stocks to Buy Right Now. Is The Biotech Sector Ready for a Breakout? On July 8, Mizuho’s healthcare strategist Jared Holz appeared on CNBC’s ...

In this article, we will examine the Top 8 Long-Term Biotechnology Stocks to Buy. Momentum in biotechnology stocks is accelerating after years of underperformance. The NASDAQ biotechnology stocks have ...

Nandita Vijayasimha, Bengaluru Thursday, January 15, 2026, 08:00 Hrs [IST] ...